Profile data is unavailable for this security.
About the company
Scandinavian ChemoTech AB is a Sweden-based company, which is primarily engaged in the healthcare industry. The Company is focused on cancer treatment and manufactures specialized medical equipment. The Company's product IQWave is an electrochemotherapy (ECT) device. The IQWave system enhances the effects of the chemotherapeutic substance by opening up small pores in the tumor cells, giving the injected chemotherapeutic substance (no more than 15 IU of bleomycin) direct access to the DNA of the target cells. Among the product's applications are hypernephroma, kaposi sarcoma, transitional cell carcinoma, head and neck squamous cell carcinoma, malignant melanoma, basal cell carcinoma. The treatment can be used for cutaneous as well as subcutaneous tumors.
- Revenue in SEK (TTM)5.03m
- Net income in SEK-15.70m
- Incorporated2013
- Employees5.00
- LocationScandinavian ChemoTech ABMedicon Village, Scheelevagen 2LUND 223 63SwedenSWE
- Websitehttps://www.chemotech.se/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Perpetua Medical AB (publ) | 6.32m | -8.48m | 19.90m | 0.00 | -- | 1.93 | -- | 3.15 | -3.06 | -3.06 | 1.91 | 2.28 | 0.4074 | 16.13 | 6.19 | -- | -54.70 | -83.52 | -74.20 | -102.19 | -65.03 | -70.52 | -134.27 | -250.30 | 6.39 | -- | 0.00 | -- | -1.76 | 57.20 | 4.63 | -- | 8.89 | -- |
| Codelab Capital AS | -98.35bn | -98.35bn | 20.17m | 29.00 | -- | 0.1298 | -- | -- | -- | -- | -- | 0.4624 | -- | -- | -- | -- | -- | -6.63 | -- | -7.43 | -- | 83.80 | -- | -39.82 | -- | -- | 0.00 | -- | -69.66 | -3.83 | 119.43 | -- | -12.19 | -- |
| Miris Holding AB (publ) | 17.32m | -9.41m | 20.46m | 10.00 | -- | 4.99 | -- | 1.18 | -0.2092 | -0.2092 | 0.3641 | 0.0271 | 0.824 | 0.1117 | 7.25 | 1,732,100.00 | -44.74 | -59.61 | -95.35 | -111.08 | 97.83 | 86.68 | -54.30 | -103.61 | 0.7091 | -8.08 | 0.0903 | -- | -17.19 | 2.53 | -20.86 | -- | -- | -- |
| Chordate Medical Holding AB (publ) | 1.12m | -27.82m | 23.72m | 3.00 | -- | 1.14 | -- | 21.12 | -41.97 | -41.97 | 1.67 | 21.16 | 0.0363 | -0.746 | 3.53 | 374,390.00 | -90.02 | -91.98 | -110.15 | -122.85 | 219.20 | 209.52 | -2,477.25 | -3,295.75 | 2.34 | -- | 0.00 | -- | 799.63 | 0.6511 | -4.45 | -- | -- | -- |
| Bio Vitos Pharma AB | 1.11m | -14.84m | 26.40m | 1.00 | -- | 0.7407 | -- | 23.81 | -1.50 | -1.50 | 0.0597 | 0.9046 | 0.0457 | 0.092 | 3.02 | 1,108,910.00 | -61.08 | -31.11 | -62.90 | -32.92 | 90.59 | -- | -1,338.03 | -1,026.76 | 5.84 | -- | 0.00 | -- | 126.97 | -- | 13.64 | -- | -- | -- |
| Inhalation Sciences Sweden AB | 15.48m | -3.93m | 26.92m | 8.00 | -- | 2.40 | -- | 1.74 | -0.2796 | -0.2796 | 1.09 | 0.7409 | 0.8096 | 0.6328 | 4.37 | 1,935,000.00 | -20.53 | -27.93 | -29.23 | -43.82 | 86.29 | 71.13 | -25.36 | -48.02 | 2.81 | -6.49 | 0.0639 | -- | 43.55 | 26.33 | 60.87 | -- | -- | -- |
| ProstaLund AB | 17.57m | -21.64m | 32.97m | 6.00 | -- | 0.4738 | -- | 1.88 | -0.2752 | -0.2752 | 0.2226 | 0.5656 | 0.2627 | 0.3308 | 12.78 | -- | -32.35 | -29.14 | -39.54 | -35.01 | 72.73 | 75.26 | -123.16 | -68.94 | 0.7618 | -155.80 | 0.1065 | -- | 27.54 | 10.36 | -53.27 | -- | 20.35 | -- |
| BBS-Bioactive Bone Substitutes Oyj | 0.00 | -41.23m | 34.05m | -- | -- | 0.6459 | -- | -- | -0.2069 | -0.2069 | 0.00 | 0.1765 | 0.00 | -- | -- | -- | -35.38 | -25.12 | -45.41 | -28.54 | -- | -- | -- | -- | -- | -27.51 | 0.5953 | -- | -- | -- | -12.64 | -- | -- | -- |
| Scandinavian ChemoTech AB | 5.03m | -15.70m | 39.26m | 5.00 | -- | 4.71 | -- | 7.80 | -0.8655 | -0.8655 | 0.2647 | 0.384 | 0.3162 | 0.5947 | 1.37 | 838,666.70 | -98.64 | -87.29 | -98.64 | -118.55 | 29.67 | 252.05 | -311.96 | -2,122.77 | -- | -22.93 | 0.00 | -- | 496.62 | 19.13 | 7.28 | -- | -- | -- |
| Scandinavian Real Heart AB | 0.00 | -75.02m | 39.40m | 12.00 | -- | 0.4305 | -- | -- | -0.5182 | -0.5182 | 0.00 | 0.4425 | 0.00 | -- | -- | 0.00 | -73.46 | -24.27 | -87.03 | -26.81 | -- | 832.41 | -- | -6,070.11 | -- | -700.38 | 0.1023 | -- | -100.00 | -- | -385.97 | -- | -25.76 | -- |
| PMD Device Solutions AB | 51.91m | -43.42m | 58.54m | 37.00 | 0.4266 | -- | -- | 1.13 | 5.06 | 5.06 | 3.54 | -5.52 | 0.8624 | -- | 4.47 | -- | -72.13 | -- | -- | -- | 82.86 | -- | -83.64 | -- | 0.1121 | -1.88 | -- | -- | -- | -- | -- | -- | -- | -- |
Data as of Nov 08 2024. Currency figures normalised to Scandinavian ChemoTech AB's reporting currency: Swedish Krona SEK
0.01%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| FCG Fonder ABas of 30 Sep 2024 | 2.32k | 0.01% |
Data from 31 Oct 2024 - 31 Oct 2024Source: FactSet Research Systems Inc.
